Technical Analysis for MRTX - Mirati Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Historical MRTX trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Earnings Movers | Other | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Fell Below 20 DMA | Bearish | -2.48% | |
| Multiple of Ten Bearish | Other | -2.48% | |
| Gapped Down | Weakness | -2.48% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -6.54% | |
| 20 DMA Support | Bullish | -8.85% | |
| Up 3 Days in a Row | Strength | -8.85% | |
| Slingshot Bearish | Bearish Swing Setup | -7.90% | |
| Crossed Above 20 DMA | Bullish | -7.90% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Down 3% | about 9 hours ago |
| Fell Below Lower Bollinger Band | about 9 hours ago |
| Down 2 % | about 9 hours ago |
| 60 Minute Opening Range Breakdown | about 10 hours ago |
| Fell Below Previous Day's Low | about 10 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/05/2021
Mirati Therapeutics Inc., a biopharmaceutical company, engages in the development of therapeutics for the cancer treatment. Its lead program in clinical development is MGCD265, a multi-targeted small molecule kinase inhibitor for treatment of oncology patients with solid tumors. The company also evaluates development opportunities in oncology for mocetinostat, a spectrum-selective HDAC inhibitor for the treatment of patients with myelodysplastic syndrome or lymphoma; and MGCD516, a kinase inhibitor with a target profile for the treatment of patients with non-small cell lung cancer and other solid tumors. Mirati Therapeutics Inc. is headquartered in San Diego, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Development Solid Tumors Oncology Chemical Compounds Lymphoma Small Cell Lung Cancer Non Small Cell Lung Cancer Cancer Treatment Targeted Therapy Myelodysplastic Syndrome Bemcentinib
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Development Solid Tumors Oncology Chemical Compounds Lymphoma Small Cell Lung Cancer Non Small Cell Lung Cancer Cancer Treatment Targeted Therapy Myelodysplastic Syndrome Bemcentinib
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 249.42 |
| 52 Week Low | 91.9 |
| Average Volume | 412,940 |
| 200-Day Moving Average | 185.12 |
| 50-Day Moving Average | 174.30 |
| 20-Day Moving Average | 160.12 |
| 10-Day Moving Average | 158.99 |
| Average True Range | 7.79 |
| ADX | 28.09 |
| +DI | 15.28 |
| -DI | 28.27 |
| Chandelier Exit (Long, 3 ATRs ) | 154.70 |
| Chandelier Exit (Short, 3 ATRs ) | 173.64 |
| Upper Bollinger Band | 169.57 |
| Lower Bollinger Band | 150.67 |
| Percent B (%b) | 0.04 |
| BandWidth | 11.80 |
| MACD Line | -4.66 |
| MACD Signal Line | -5.21 |
| MACD Histogram | 0.5523 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 163.26 | ||||
| Resistance 3 (R3) | 164.30 | 161.41 | 161.30 | ||
| Resistance 2 (R2) | 161.41 | 158.42 | 160.90 | 160.65 | |
| Resistance 1 (R1) | 156.46 | 156.57 | 155.02 | 155.43 | 160.00 |
| Pivot Point | 153.58 | 153.58 | 152.86 | 153.06 | 153.58 |
| Support 1 (S1) | 148.63 | 150.59 | 147.19 | 147.59 | 143.02 |
| Support 2 (S2) | 145.74 | 148.74 | 145.23 | 142.37 | |
| Support 3 (S3) | 140.79 | 145.74 | 141.72 | ||
| Support 4 (S4) | 139.76 |
